These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17335312)

  • 21. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).
    Lieberman JA
    Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808
    [No Abstract]   [Full Text] [Related]  

  • 22. In the aftermath of CATIE: how should administrators value atypical antipsychotic medications?
    Luchins DJ
    Adm Policy Ment Health; 2006 Sep; 33(5):541-3. PubMed ID: 16688482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy.
    Davies LM; Lewis S; Jones PB; Barnes TR; Gaughran F; Hayhurst K; Markwick A; Lloyd H;
    Br J Psychiatry; 2007 Jul; 191():14-22. PubMed ID: 17602120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
    Thomas P
    Eur Neuropsychopharmacol; 2007 Mar; 17 Suppl 2():S115-22. PubMed ID: 17336766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
    Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
    J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost-effectiveness of atypicals in the UK.
    Heeg B; Buskens E; Botteman M; Caleo S; Ingham M; Damen J; de Charro F; van Hout B
    Value Health; 2008 Dec; 11(7):1007-21. PubMed ID: 18489517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Newer atypical antipsychotic medication versus clozapine for schizophrenia.
    Tuunainen A; Wahlbeck K; Gilbody SM
    Cochrane Database Syst Rev; 2000; (2):CD000966. PubMed ID: 10796559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The NIMH-CATIE Schizophrenia Study: what did we learn?
    Lieberman JA; Stroup TS
    Am J Psychiatry; 2011 Aug; 168(8):770-5. PubMed ID: 21813492
    [No Abstract]   [Full Text] [Related]  

  • 30. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.
    Kruse G; Wong BJ; Duh MS; Lefebvre P; Lafeuille MH; Fastenau JM
    Pharmacoeconomics; 2015 Oct; 33(10):1049-67. PubMed ID: 25963579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cost-effectiveness of Antipsychotics in the Maintenance Treatment of Schizophrenia in Colombia].
    Quitian Reyes H; Arciniegas Barrera JA; Bohórquez Peñaranda A; Gómez Restrepo C
    Rev Colomb Psiquiatr; 2016; 45(2):67-74. PubMed ID: 27132755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
    Achilla E; McCrone P
    Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The CATIE schizophrenia trial: results, impact, controversy.
    Manschreck TC; Boshes RA
    Harv Rev Psychiatry; 2007; 15(5):245-58. PubMed ID: 17924259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing a policy for second-generation antipsychotic drugs.
    Rosenheck RA; Sernyak MJ
    Health Aff (Millwood); 2009; 28(5):w782-93. PubMed ID: 19622538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.
    Caroff SN; Hurford I; Lybrand J; Campbell EC
    Neurol Clin; 2011 Feb; 29(1):127-48, viii. PubMed ID: 21172575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.